Personalizing therapies for gastric cancer: Molecular mechanisms and novel targeted therapies

被引：8

作者：

Michael Luis ^{[1
,2
]}

Ana Tavares ^{[2
]}

Liliana S Carvalho ^{[3
,4
]}

Lúcio Lara-Santos ^{[2
,5
]}

António Araújo ^{[1
]}

Ramon Andrade de Mello ^{[1
,6
]}

机构：

[1] Gastrointestinal Unit,Service of Medical Oncology,Portuguese Oncology Institute,4200-072 Porto,Portugal

[2] Gastrointestinal Unit,Experimental Pathology and Therapeutics Group,Research Center-Portuguese Oncology Institute,4200-072 Porto,Portugal

[3] Department of Pharmacology and Therapeutics,Faculty of Medicine,University of Porto,4200-319 Porto,Portugal

[4] Institute of Cellular and Molecular Biology,4150-180 Porto,Portugal

[5] Gastrointestinal Unit,Section of Surgical Oncology,Portuguese Oncology Institute,4200-072 Porto,Portugal

[6] Department of Medicine,Faculty of Medicine,University of Porto,4200-319 Porto,Portugal

来源：

World Journal of Gastroenterology | 2013年 / 19卷 / 38期

关键词：

Gastric cancer; Human epidermal growth factor receptor 2; Biomarkers; Target therapies; Trastuzumab; Lapatinib; Pertuzumab; Trastuzumab-DM1; Afatinib;

D O I：

暂无

中图分类号：

R735.2 [胃肿瘤];

学科分类号：

100214 ;

摘要：

Globally,gastric cancer is the 4thmost frequently diagnosed cancer and the 2ndleading cause of death from cancer,with an estimated 990000 new cases and738000 deaths registered in 2008.In the advanced setting,standard chemotherapies protocols acquired an important role since last decades in prolong survival.Moreover,recent advances in molecular therapies provided a new interesting weapon to treat advanced gastric cancer through anti-human epidermal growth factor receptor 2(HER2)therapies.Trastuzumab,an anti-HER2 monoclonal antibody,was the first target drug in the metastatic setting that showed benefit in overall survival when in association with platinum-5-fluorouracil based chemotherapy.Further,HER2 overexpression analysis acquired a main role in predict response for trastuzumab in this field.Thus,we conducted a review that will discuss the main points concerning trastuzumab and HER2 in gastric cancer,providing a comprehensive overview of molecular mechanisms and novel trials involved.

引用

页码：6383 / 6397

页数：15

共 47 条

[1] Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer[J]. Chao He,Xue-Yi Bian,Xing-Zhi Ni,Dan-Ping Shen,Yan-Ying Shen,Hua Liu,Zhi-Yong Shen,Qiang Liu.World Journal of Gastroenterology. 2013(14)
[2] Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma[J]. Shi-Yan Yan,Ying Hu,Jian-Gao Fan,Department of Gastroenterology,Xinhua Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200092,China Guo-Quan Tao,Department of General Surgery,Huaian No.1 People’s Hospital affiliated to Nanjing Medical University,Huaian 223300,Jiangsu Province,China Yong-Ming Lu,Xu Cai,Bao-Hua Yu,Department of Pathology,Cancer Hospital,Fudan University,
[3] Inhibition of gastric tumor growth by a novel Hsp90 inhibitor[J] . Chunwan Lu,Di Liu,Jing Jin,Hemantkumar Deokar,Yi Zhang,John K. Buolamwini,Xiaoming Yu,Chunhong Yan,Xiaoguang Chen.Biochemical Pharmacology . 2013
[4] HER2 expression and its clinicopathological features in resectable gastric cancer
Kataoka, Yoshiki
Okabe, Hiroshi
Yoshizawa, Akihiko
Minamiguchi, Sachiko
Yoshimura, Kenichi
Haga, Hironori
Sakai, Yoshiharu
[J]. GASTRIC CANCER, 2013, 16 (01) : 84 - 93
[5] Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer[J] . Alicia F.C. Okines,David Cunningham.Therapeutic Advances in Gastroenterology . 2012 (5)
[6] Advanced HER2-positive gastric cancer: Current and future targeted therapies[J] . Roberto A. Pazo Cid,Antonio Antón.Critical Reviews in Oncology / Hematology . 2012
[7] Targeted Therapy for Gastric Cancer
Smyth, Elizabeth C.
Cunningham, David
[J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (03) : 377 - 389
[8] Insight into p95HER2 in Breast Cancer: Molecular Mechanisms and Targeted Therapies[J] . Ramon Andrade de Mello,Alessandro de Vasconcelos,Ronaldo A Ribeiro,Ines Pousa,Noemia Afonso,Deolinda Pereira,Helena Rodrigues.Recent Patents on DNA and Gene Sequences . 2012 (1)
[9] Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-A systematic review
Chua, Terence C.
Merrett, Neil D.
[J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (12) : 2845 - 2856
[10] A phase II study of afatinib （BIBW 2992）, an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab[J] . Nancy Lin,Eric Winer,Duncan Wheatley,Lisa Carey,Stephen Houston,David Mendelson,Pamela Munster,Laurie Frakes,Steve Kelly,Agustin Garcia,Susan Cleator,Martina Uttenreuther-Fischer,Hilary Jones,Sven Wind,Richard Vinisko,Tamas Hickish.Breast Cancer Research and Treatment . 2012 (3)

← 1 2 3 4 5 →